Compare ALG & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALG | TYRA |
|---|---|---|
| Founded | 1955 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1996 | 2021 |
| Metric | ALG | TYRA |
|---|---|---|
| Price | $168.12 | $36.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $225.00 | $47.50 |
| AVG Volume (30 Days) | 120.4K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 8.59 | N/A |
| Revenue | ★ $1,603,715,000.00 | N/A |
| Revenue This Year | $5.26 | N/A |
| Revenue Next Year | $3.97 | N/A |
| P/E Ratio | $20.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $156.30 | $8.75 |
| 52 Week High | $233.29 | $40.65 |
| Indicator | ALG | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 51.84 |
| Support Level | $168.24 | $34.01 |
| Resistance Level | $174.00 | $39.90 |
| Average True Range (ATR) | 5.29 | 2.05 |
| MACD | 0.64 | -0.35 |
| Stochastic Oscillator | 24.88 | 38.00 |
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Its products include agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck-mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, snow removal equipment, etc. The company's reportable segments are Vegetation Management, which generates the maximum revenue, and Industrial Equipment. Geographically, the company generates maximum revenue from the United States, followed by Canada, France, the UK, Brazil, the Netherlands, and other regions.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.